Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Aug 16, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Next-Generation Chimeric Antigen Receptor T-cells.

Dongni Yi¹, Mia Gergis², Jingmei Hsu³

¹Thomas Jefferson University Sidney Kimmel Medical College, USA.

Hematology/Oncology and Stem Cell Therapy

|December 20, 2022

Summary

Chimeric antigen receptor T cell (CAR-T) therapy has advanced cancer treatment, but challenges like recurrence and solid tumor application persist. Newer CAR-T generations aim to overcome these limitations for broader patient benefit.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma.

Haematologica·2026

Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026

Same author

Reduced-Dose Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Stem Cell Transplantation: A Systematic Review of Efficacy and Toxicity.

Transplantation and cellular therapy·2026

Same author

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Transplantation and cellular therapy·2026

Same author

MRD-guided de-escalation of TBI conditioning in ALL.

Bone marrow transplantation·2026

Same author

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Transplantation and cellular therapy·2026

Area of Science:

Immunotherapy
Cellular Therapy
Oncology

Background:

The U.S. Food and Drug Administration (FDA) has approved six Chimeric Antigen Receptor T cell (CAR-T) products within five years, revolutionizing treatment for B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM).
Despite significant improvements, challenges such as cancer recurrence and progression after CAR-T therapy, along with limited application in solid tumors, remain critical issues.

Approach:

This review examines the historical development and evolution of CAR-T cell therapies.
It explores how next-generation CAR-T cells are being engineered to address current therapeutic barriers and overcome resistance mechanisms.

Key Points:

Recent FDA approvals highlight the growing impact of CAR-T therapies in hematologic malignancies.
Mechanisms of recurrence and progression necessitate further innovation in CAR-T cell design.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Aug 16, 2025

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Barriers to CAR-T cell therapy in solid tumors are a major focus for future research and development.

Conclusions:

The ongoing evolution of CAR-T cell technology holds promise for enhancing efficacy and expanding treatment to a wider range of cancers, including solid tumors.
Future CAR-T cell generations are expected to offer improved persistence, safety, and broader applicability, potentially transforming the landscape of cancer immunotherapy.